WhaleCreep

Blue Water Life Science Advisors, LP 13F holdings, Q4 2024

Holdings as of December 31, 2024 · filings on SEC EDGAR · latest filing →

Blue Water Life Science Advisors, LP disclosed 9 US equity positions worth $112.9m in its Q4 2024 13F filing. The largest position was NTRA at 35.7% of the reported book, followed by GH and CDNA. Against the Q3 2024 filing, it opened 1 new position, added to 2 and reduced 2 among the top 9 holdings.

← Q3 2024 · Q1 2025 →

What did Blue Water Life Science Advisors, LP own in Q4 2024? Top 9 positions

#StockSectorWeightValueSharesΔ sharesvs Q3 2024
1 NTRA NATERA INC Healthcare 35.7%$40.3m254,794 -12% reduced
2 GH GUARDANT HEALTH INC Healthcare 18.8%$21.2m694,047 54% added
3 CDNA CAREDX INC Healthcare 11.5%$12.9m604,000 0% held
4 ADPT ADAPTIVE BIOTECHNOLOGIES COR Healthcare 11.4%$12.9m2,145,145 0% held
5 AKOYA BIOSCIENCES INC 9.5%$10.8m4,697,785 0% held
6 PSNL PERSONALIS INC Healthcare 5.8%$6.5m1,132,900 13% added
7 EXK EXACT SCIENCES CORP Basic Materials 3.9%$4.4m78,843 -69% reduced
8 TEM TEMPUS AI INC Healthcare 2.7%$3.0m90,000 – new
9 QTRX QUANTERIX CORP Healthcare 0.7%$833.3k78,393 0% held

Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.